Human phenotypes and animal knockout models of genetic autonomic disorders

Journal of Biomedical Science

Volumn 11, Issue 1, 2004, Pages 4-10

  Usera, Phillip C ^a   Vincent, Simi ^a   Robertson, David ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Catecholamines; Dopamine hydroxylase; Norepinephrine transporter; Vesicular monoamine transporter subtype 2

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLONIDINE; DOPAMINE BETA MONOOXYGENASE; METHYLDOPA; NORADRENALIN; NORADRENALIN TRANSPORTER;

AUTONOMIC DYSFUNCTION; CLINICAL FEATURE; DISEASE MODEL; ENZYME DEFICIENCY; EXPERIMENTAL MODEL; EXPERIMENTAL MOUSE; EXPERIMENTATION; FETUS DEVELOPMENT; GENETIC DISORDER; HUMAN; KNOCKOUT MOUSE; MOLECULAR DYNAMICS; NONHUMAN; ORTHOSTATIC HYPOTENSION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; REVIEW; WILD TYPE;

ANIMALS; AUTONOMIC NERVOUS SYSTEM DISEASES; DISEASE MODELS, ANIMAL; DOPAMINE BETA-HYDROXYLASE; HUMANS; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MICE; MICE, KNOCKOUT; NEUROPEPTIDES; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; PHENOTYPE; SYMPORTERS; VESICULAR BIOGENIC AMINE TRANSPORT PROTEINS; VESICULAR MONOAMINE TRANSPORT PROTEINS;

ANIMALIA;

EID: 0942300672     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1159/000075283     Document Type: Review

References (38)

1. Axelrod J: Dopamine-β-hydroxylase: Regulation of its synthesis and release from nerve terminals. Pharmacol Rev 1972;24:233-243.
2. Carson RP, Appalsamy M, Diedrich A, Davis TL, Robertson D: Animal model of the neuropathic tachycardia syndrome. Hypertension 2001;37:1357-1361.
3. Carson RP, Robertson D: Genetic manipulation of noradrenergic neurons. J Pharmacol Exp Ther 2002;301:410-417.
4. Cho M, Rao M, Koch WJ, Thomas SA, Palmiter RD, Rockman HA: Enhanced contractility and decreased beta-adrenergic receptor kinase-1 in mice lacking endogenous norepinephrine and epinephrine. Circulation 1999;99:2702-2707.
5. Derogatis LR: SCL-90-R: Administration, Scoring and Procedures Manual-I for the Revised Version. Baltimore, Johns Hopkins University School of Medicine, 1977.
6. Dhawan S, Duong LE, Ornberg RL, Fleming PJ: Subunit exchange between membranous and soluble bovine forms of dopamine β-hydroxylase. J Biol Chem 1987;262:1869-1875.
7. Eisenhofer G, Smolich JJ, Esler MD: Disposition of endogenous adrenaline compared to noradrenaline released by cardiac sympathetic nerves in the anesthetized dog. Nauyn Schmiedeberg's Arch Pharmacol 1992;345:160-171.
8. Garland EM, Hahn MK, Ketch TP, Keller NR, Kim C, Kim K, Biaggioni I, Shannon JR, Blakely RD, Robertson D: Genetic basis of catecholamine disorders. Ann NY Acad Sci 2002;971:506-514.
9. Goldstein DS, Eisenhofer G, Kopin IJ: Sources and significance of plasma levels of catechols and their metabolites in humans. Perspec Pharmacol 2003;305:800-811.
10. Hahn MK, Blakely RD: Monoamine transporter gene structure and polymorphisms in relation to psychiatric and other complex disorders. Pharmacogenom J 2002;2:217-235.
11. Hahn MK, Robertson D, Blakely RD: A mutation in the human norepinephrine transporter gene (SLC6A2) associated with orthostatic intolerance disrupts surface expression of mutant and wild-type transporters. J Neurosci 2003;23:4470-4478.
12. Itokawa K, Sora I, Schindler CW, Itokawa M, Takahashi N, Uhl GR: Heterozygous VMAT2 knockout mice display prolonged QT intervals: Possible contributions to sudden death. Mol Brain Res 1999;71:354-357.
13. Jacob G, Biaggioni I: Idiopathic orthostatic intolerance and postural tachycardia syndromes. Am J Med Sci 1999;317:88-101.
14. Keller N, Diedrich A, Appalsamy M, Tuntrakool S: Impaired cardiovascular regulation in the norepinephrine transporter (NET) knockout mouse. Clin Auton Res 2003; in press.
15. Keller N, Diedrich A, Appalsamy M, Caron MG, Robertson D: Excessive stress-induced tachycardia in the norepinephrine transporter (NET) knockout mouse. Clin Auton Res 2003; in press.
16. Kim CH, Hwang DY, Park JJ, Kim KS: A proximal promoter domain containing a homeodomain-binding core motif interacts with multiple transcription factors, including HoxA5 and Phox2A proteins, and critically regulates cell type-specific transcription of the human norepinephrine transporter gene. J Neurosci 2002;22:2579-2589.
17. Kim CH, Zabetian CP, Cubells, JF, Cho S, Biaggioni I, Cohen BM, Robertson D, Kim KS: Mutations in the dopamine β-hydroxylase gene are associated with human norepinephrine deficiency. Am J Med Genet 2002;108:140-147.
18. Liu Y, Edwards RH: The role of vesicular transport proteins in synaptic transmission and neural degeneration. Annu Rev Neurosci 1997;20:125-156.
19. Little KY, Krolewski DM, Zhang L, Cassin BJ: Loss of striatal vesicular monoamine transporter (VMAT2) in human cocaine users. Am J Psych 2003;160:47-55.
20. Lucki I, Page ME, Cryan JF: Noradrenergic lesions differentially alter the antidepressant-like effects of reboxetine. Soc Neurosci Abstr 2000;26:1043.
21. Mahata M, Mahata SK, Parmer RJ, O'Connor DT: Vesicular monoamine transport inhibitors: Novel action at calcium channels to prevent catecholamine secretion. Hypertension 1996;28:414-420.
22. Man in't Veld AJ, Boomsma F, Moleman P, Schalekamp MADH: Congenital dopamine-β-hydroxylase deficiency: a novel orthostatic syndrome. Lancet 1987;i:183-187.
23. Mills PA, Huetteman DA, Brockway BP, Zwiers LM, Gelsema AJ, Schwartz RS, Kramer K: A new method of for measurement of blood pressure, heart rate, and activity in the mouse by radiotelemetry. J Appl Physiol 2000;88:1537-1544.
24. O'Connor DT, Cervenka JH, Stone RA, Levine GL, Parmer RJ, Franco-Bourland RE, Madrazo I, Langlais PJ, Robertson D, Biaggioni I: Dopamine β-hydroxylase immunoreactivity in human cerebrospinal fluid: properties, relationship to central noradrenergic neuronal activity and variation in Parkinson's disease and congenital dopamine β-hydroxylase deficiency. Clin Sci (Colch) 1994;86:149-158.
25. Richer C, Domergue V, Gervais M, Bruneval R, Giudicelli JF: Fluospheres for cardiovascular phenotyping genetically modified mice. J Cardiovasc Pharm 2000;36:396-404.
26. Robertson D, Flattem N, Tellioglu T, Carson R, Garland E, Shannon JR, Jordan J, Jacob G, Blakely RD, Biaggioni I: Familial orthostatic tachycardia due to norepinephrine transporter deficiency. Ann NY Acad Sci 2001;940:527-543.
27. Robertson D, Goldberg MR, Hollister As, Onrot J, Wiley R, Thompson JG, Robertson RM: Isolated failure of autonomic noradrenergic transmission: Evidence of impaired [beta]-hydroxylation of dopamine. N Engl J Med 1986;314:1494-1497.
28. Robertson D, Perry SE, Hollister AS, Robertson RM, Biaggioni I: Dopamine-β-hydroxylase deficiency: A genetic disorder of cardiovascular regulation. Hypertension 1991;18:1-8.
29. Schroeder C, Tank J, Boschmann M, Diedrich A, Sharma A, Biaggioni I, Luft F, Jordan J: Selective norepinephrine reuptake inhibition as a human model of orthostatic intolerance. Circulation 2002;105:347-353.
30. Shannon JR, Flattem NL, Jordan J, Jacob G, Black B, Biaggioni I, Blakely RD, Robertson D: Orthostatic intolerance and tachycardia associated with norepinephrine transporter deficiency. N Engl J Med 2000;342:541-549.
31. Sung U, Apparsundaram S, Galli A, Kahlig KM, Savchenko V, Schroeter S, Quick MW, Blakely RD: A regulated interaction of syntax-in 1A with the antidepressant-sensitive norepinephrine trnasporter establishes catecholamine clearance capacity. J Neurosci 2003;23:1697-1709.
32. Thomas SA, Matsumoto AM, Palmiter RD: Noradrenaline is essential for mouse fetal development. Nature (Lond) 1995;374:643-646.
33. Thomas SA, Palmiter RD: Thermoregulatory and metabolic phenotypes of mice lacking nor-adrenaline and adrenaline. Nature (Lond) 1997;387:94-97.
34. Torres GE, Gainetdinov RR, Caron MG: Plasma membrane monoamine transporters: structure regulation and function. Nat Rev Neurosci 2003;4:13-25.
35. Uhl GR, Li SU, Takahashi N, Itokawa K, Lin Z, Hazama M, Sora I: The VMAT2 gene is mice and humans: amphetamine responses, locomotion, cardiac arrhythmias, aging, and vulnerability to dopaminergic toxins. FASEB J 2000;14:2459-2465.
36. Van Vliet BN, Chafe LL, Antic V, Schnyder-Candrian S, Montani JP: Direct and indirect methods used to study arterial blood pressure. J Pharmacol Toxicol Methods 2000;44:361-373.
37. Vincent S, Bieck PR, Garland EM, Robertson D: Clinical assessment of norepinephrine transporter blockade through biochemical and pharmacological profiling. J Invest Med 2003;51:2,103.
38. Vincent S, Robertson D: The broader view: Catecholamine abnormalities. Clin Auton Res 2002;12:44-49.